How many insider trades does FilingIQ track for DMAC?

FilingIQ tracks 114 Form 4 insider transactions for DMAC (DiaMedica Therapeutics Inc.), covering filings from Dec 11, 2018 onwards. 9 of those were filed in the last 90 days.

Are DMAC insiders net buyers or net sellers?

Across the full Form 4 history for DMAC, 69 transactions (61%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DMAC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DMAC in?

DiaMedica Therapeutics Inc. (DMAC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $357.25M.

DMAC insider trading

NasdaqCM Healthcare

DiaMedica Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

114

Last 90 days

Buys / sells

61% / 1%

Market cap

$357.25M

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Company website: www.diamedica.com

DMAC insider activity at a glance

FilingIQ has scored 114 insider transactions for DMAC since Dec 11, 2018. The most recent filing in our index is dated Jun 1, 2026.

Across the full history, 69 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DMAC insider trades is 53.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DMAC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,234

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 187

Guardant Health, Inc.

BMY 182

BRISTOL MYERS SQUIBB CO

HOLX 142

HOLOGIC INC

ADPT 140

Adaptive Biotechnologies Corp

KNSA 139

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for DMAC?: FilingIQ tracks 114 Form 4 insider transactions for DMAC (DiaMedica Therapeutics Inc.), covering filings from Dec 11, 2018 onwards. 9 of those were filed in the last 90 days.
Are DMAC insiders net buyers or net sellers?: Across the full Form 4 history for DMAC, 69 transactions (61%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DMAC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DMAC in?: DiaMedica Therapeutics Inc. (DMAC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $357.25M.

Methodology & sources

Every DMAC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.